Sagimet Biosciences, Inc. Class A ( (SGMT) ) has released its Q3 earnings. Here is a breakdown of the information Sagimet Biosciences, Inc. Class A presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting metabolic and fibrotic pathways, primarily through fatty acid synthase (FASN) inhibitors, with a focus on conditions like MASH and acne.
In its latest earnings report for the third quarter of 2025, Sagimet Biosciences provided updates on its ongoing clinical trials and financial performance. The company highlighted its efforts in exploring the therapeutic potential of FASN inhibition across various indications, including the initiation of a Phase 1 trial for a combination of denifanstat and resmetirom, and the ongoing development of TVB-3567 for acne treatment.
Key financial metrics from the report include a decrease in research and development expenses to $9.7 million for the quarter, compared to $12.7 million in the same period last year. General and administrative expenses slightly increased to $4.6 million. The company reported a net loss of $12.9 million for the quarter, a reduction from the $14.6 million loss reported in the previous year. Sagimet’s cash and marketable securities stood at $125.5 million as of September 30, 2025.
Strategically, Sagimet is advancing its clinical programs with anticipated milestones, including the data readout from its Phase 1 trial in the first half of 2026 and potential progression to Phase 2 trials for both MASH and acne indications. The company also announced key promotions within its leadership team, reflecting its commitment to scientific and legal excellence.
Looking ahead, Sagimet Biosciences remains focused on advancing its clinical trials and exploring the potential of its FASN inhibitors to address unmet medical needs in metabolic and fibrotic conditions. The company aims to leverage positive trial outcomes to progress its drug candidates through regulatory pathways and into broader clinical applications.